Alan L Parker (A Parker)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 26

Top Topics

Binding Protein

Respiratory Syndrome Coronavirus

Top Venues

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Rebecca Wallace, Carly M Bliss, Alan L Parker
The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies. Viruses 16 (6) (2024)
Rebecca Wallace, Carly M Bliss, Alan L Parker
The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies. Viruses 16 (6) (2024)
Joshua Gardner, Simon Timothy Abrams, Cheng-Hock Toh, Alan L Parker, Charlotte Lovatt, Phillip Lindsay Ross Nicolson, Steve P Watson, Sophie Grice, Luisa Hering, Munir Pirmohamed, Dean J Naisbitt
Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines. NPJ vaccines 9 (1) (2024)
Rebecca Wallace, Carly M Bliss, Alan L Parker
The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies. Viruses 16 (6) (2024)
Joshua Gardner, Simon Timothy Abrams, Cheng-Hock Toh, Alan L Parker, Charlotte Lovatt, Phillip Lindsay Ross Nicolson, Steve P Watson, Sophie Grice, Luisa Hering, Munir Pirmohamed, Dean J Naisbitt
Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines. NPJ vaccines 9 (1) (2024)
Joshua Gardner, Simon Timothy Abrams, Cheng-Hock Toh, Alan L Parker, Charlotte Lovatt, Phillip Lindsay Ross Nicolson, Steve P Watson, Sophie Grice, Luisa Hering, Munir Pirmohamed, Dean J Naisbitt
Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines. NPJ vaccines 9 (1) (2024)
Charlotte Lovatt, Alan L Parker
Oncolytic Viruses and Immune Checkpoint Inhibitors: The "Hot" New Power Couple. Cancers 15 (16) (2023)
Emily A Bates, Charlotte Lovatt, Alice R Plein, James A Davies, Florian A Siebzehnrübl, Alan L Parker
Engineering Adenoviral Vectors with Improved GBM Selectivity. Viruses 15 (5) (2023)
Tabitha G Cunliffe, Alan L Parker, Alfonso Jaramillo
Pseudotyping Bacteriophage P2 Tail Fibers to Extend the Host Range for Biomedical Applications. ACS synthetic biology 11 (10) (2022)
Emily A Bates, John R Counsell, Sophie Alizert, Alexander T Baker, Natalie Suff, Ashley K Boyle, Angela C Bradshaw, Simon N Waddington, Stuart A Nicklin, Andrew H Baker, Alan L Parker
In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications. Viruses 13 (8) (2021)
Alicia Teijeira Crespo, Stephanie Burnell, Lorenzo Capitani, Rebecca Bayliss, Elise Moses, Georgina H Mason, James A Davies, Andrew J Godkin, Awen M Gallimore, Alan L Parker
Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163 (4) (2021)
James A Davies, Gareth Marlow, Hanni K Uusi-Kerttula, Gillian Seaton, Luke Piggott, Luned M Badder, Richard W E Clarkson, John D Chester, Alan L Parker
Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5NULL-A20. Viruses 13 (5) (2021)
Alexander T Baker, Ryan J Boyd, Daipayan Sarkar, Alicia Teijeira-Crespo, Chun Kit Chan, Emily Bates, Kasim Waraich, John W Vant, Eric A Wilson, Chloe D Truong, Magdalena Lipka-Lloyd, Petra Fromme, Josh Vincent Vermaas, Dewight R Williams, LeeAnn Machiesky, Meike Heurich, Bolni M Nagalo, Lynda Coughlan, Scott Umlauf, Po-Lin Chiu, Pierre J Rizkallah, Taylor S Cohen, Alan L Parker, Abhishek Singharoy, Mitesh J Borad
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science advances 7 (49) (2021)
Sophia J Tate, Leen Van de Sande, Wim P Ceelen, Jared Torkington, Alan L Parker
The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses. Pharmaceutics 13 (12) (2021)
Davor Nestić, Ksenija Bozinovic, Isabela Drašković, Rebecca Wallace, Alan L Parker, Dragomira Majhen
The Revolving Door of Adenovirus Cell Entry: Not All Pathways Are Equal. Pharmaceutics 13 (10) (2021)
Alexander T Baker, James A Davies, Emily A Bates, Elise Moses, Rosie M Mundy, Gareth Marlow, David K Cole, Carly M Bliss, Pierre J Rizkallah, Alan L Parker
The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism. Journal of virology 95 (4) (2021)
Maha Othman, Alexander T Baker, Elena Gupalo, Abdelrahman Elsebaie, Carly M Bliss, Matthew T Rondina, David Lillicrap, Alan L Parker
To clot or not to clot? Ad is the question-Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia. Journal of thrombosis and haemostasis : JTH 19 (11) (2021)
Tabitha G Cunliffe, Emily A Bates, Alan L Parker
Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies. Cancers 12 (11) (2020)
Nicholas George Mowbray, J Ansell, J Horwood, J Cornish, P Rizkallah, Alan L Parker, P Wall, Antonino Spinelli, Jared Torkington
Safe management of surgical smoke in the age of COVID-19. The British journal of surgery 107 (11) (2020)
Martin J Scurr, Alex Greenshields-Watson, Emma Campbell, Michelle S Somerville, Yuan Chen, Sarah L Hulin-Curtis, Stephanie E A Burnell, James A Davies, Michael M Davies, Rachel Hargest, Simon Phillips, Adam D Christian, Kevin E Ashelford, Robert Andrews, Alan L Parker, Richard James Stanton, Awen Gallimore, Andrew Godkin
Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (13) (2020)
Sarah L Hulin-Curtis, James A Davies, Davor Nestić, Emily A Bates, Alexander T Baker, Tabitha G Cunliffe, Dragomira Majhen, John D Chester, Alan L Parker
Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer gene therapy 27 (10-11) (2020)
Michael D Crowther, Garry Dolton, Mateusz Legut, Marine E Caillaud, Angharad Lloyd, Meriem Attaf, Sarah A E Galloway, Cristina Rius, Colin P Farrell, Barbara Szomolay, Ann Ager, Alan L Parker, Anna Fuller, Marco Donia, James McCluskey, Jamie Rossjohn, Inge Marie Svane, John D Phillips, Andrew K Sewell
Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature immunology 21 (2) (2020)
Y K Stella Man, Julie Foster, Elisabete Carapuça, James A Davies, Alan L Parker, Jane Sosabowski, Gunnel Halldén
Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific reports 9 (1) (2019)
Alexander T Baker, Rosie M Mundy, James A Davies, Pierre J Rizkallah, Alan L Parker
Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor. Science advances 5 (9) (2019)
Alexander T Baker, Alexander Greenshields-Watson, Lynda Coughlan, James A Davies, Hanni Uusi-Kerttula, David K Cole, Pierre J Rizkallah, Alan L Parker
Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nature communications 10 (1) (2019)
Alexander T Baker, Carmen Aguirre-Hernández, Gunnel Halldén, Alan L Parker
Designer Oncolytic Adenovirus: Coming of Age. Cancers 10 (6) (2018)